1 / 74

A Closer Look at Clostridium difficile Infections

A Closer Look at Clostridium difficile Infections. Richard Allan Bettis , Fourth-Year Pharm.D . Candidate Preceptor: Dr. Ali Rahimi University of Georgia College of Pharmacy. Background. Clostridium species >190 species identified Gram-positive Anaerobic Spore forming bacilli

phyllis-martinez
Download Presentation

A Closer Look at Clostridium difficile Infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Closer Look at Clostridium difficileInfections Richard Allan Bettis, Fourth-Year Pharm.D. Candidate Preceptor: Dr. Ali Rahimi University of Georgia College of Pharmacy

  2. Background • Clostridium species • >190 species identified • Gram-positive • Anaerobic • Spore forming bacilli • Releases exotoxins which are associated with major diseases in humans C. difficile colitis results from the ingestion of spores that vegetate, multiply, and secrete toxins

  3. Background • Clostridium tetani • Causes tetanus through spread of potent neurotoxin • Clostridium botulinum • Causes botulism through spread of potent neurotoxins • Clostridium perfringens • Causes gas gangrene through spread of necrotizing, hemolytic exotoxin • Clostridium difficile • Causes pseudomembranous colitis through production of cytotoxin and enterotoxin • Relatively resistant to most commonly used antibiotics • Found in normal gut flora of 2-10% of humans

  4. Pathophysiology • Toxin A, the enterotoxin, causes: • Damage to intestinal mucosa • Intestinal fluid secretion • Inflammation via actin disaggregation • Intracellular calcium release • Damage to neurons in the gut • Toxin B, the cytotoxin, causes: • Depolymerization of filamentous actin • More effective damage to colonic mucosa

  5. Pathogenesis • Pseudomembranous plaques formation resulting in inflammation of mucosa • Enlargement and spread of plaques through gut results in clinical presentation • Mild to severe diarrhea • Mucosal necrosis • Accumulation of inflammatory cells and fibrin Raised, yellowish-white pseudomembranous plaques

  6. Background • Clostridium difficileinfection (CDI) is the most common cause of infectious diarrhea in hospitalized patients • Once antibiotics disrupt normal gut flora: • C. difficilecolonization occurs • Toxins production results in manifestation of CDI • Diarrhea and colitis results • CDI should be suspected in any patients with diarrhea with recent history of antibiotic use

  7. CDI Risk Factors • Clostridium difficileinfections occur most often in high risk groups: • Elderly (>65 years old) • Debilitated • Immunocompromised • Surgical patients • Nasogastric tubes • Frequent laxative use • History of antibiotic use

  8. CDI Risks • CDI can occur during, shortly after, or several months after the use of broad spectrum antimicrobial treatment • CDI should be suspect in any patients with diarrhea with recent history of antibiotic use within the past THREE MONTHS • Patients whose diarrhea began 72 HOURS after hospitalization

  9. CDI-Associated Antimicrobials • Broad spectrum antimicrobials associated with CDIs: • Clindamycin • Ampicillin • Flouroquinolones • Ciprofloxacin, levofloxacin, moxifloxacin • Cephalosporins(2nd & 3rd generation) • Cefotaxime, ceftriaxone, cefuroxime, ceftazidime • Aminoglycosides • Erythromycin • TMP-SMX • Metronidazole • Vancomycin Used to treat CDI!

  10. Clinical Presentation • Patients with CDI often present with: • Watery or perfuse diarrhea (as many as 20 bowel movements per day) • Leukocytosis (50%) • Fever (28%) • Abdominal pain (22%) • Ileus (~20%) • Pseudomembraneformation • Malaise • Nausea • Anorexia

  11. Clinical Presentation • Clinical diagnosis based upon diarrhea onset during or after antimicrobial use • Delay in diagnosis can result in complications : • Life-threatening toxic megacolon • Pseudomembranous enterocolitis

  12. Diagnosis • Pathogens most often responsible for infectious diarrhea or enteritis: • Shigellaspecies • Salmonella species • Escherichia coli • Yersinia species • Vibrio species • Clostridium difficile • Other etiologies less commonly seen or in extreme cases of immunodeficiency • Parasites (Entamoebahistolytica, Giardia lamlia) • Viruses (Cytomegalovirus)

  13. Differential Diagnosis • Stool cultures are crucial to making an organism-specific diagnoses and determining antimicrobial sensitivity • Recommended in patients with inflammatory diarrhea • Poor yield of positive cultures • If negative, then a 2nd analysis is recommended

  14. Diagnosis • Detection of toxins • C. difficiletoxins A or B • Enzyme assays for • Glutamate dehydrogenase (GDH) • Endoscopy • Reserved when rapid diagnosis is needed • Used when ileus is present • Stool samples are unavailable • Differential diagnoses with concurrent colonic diseases Raised, yellowish-white pseudomembranous plaques characteristic of CDI

  15. Prevention • Clostridium difficilecan be cultured in rooms of infected individuals UP TO 40 DAYS after discharge • Strict hand washing • Contact precautions • Vaccines?

  16. Clostridium difficilecan be cultured in rooms of infected individuals UP TO 40 DAYS after discharge

  17. Is There A Problem? • Most frequently acquired exogenously from: • Hospital • Nursing home • Long-term care facility • >20% fecal colonization among patients hospitalized for >1 week • C. difficilespores can persist for months on most surfaces • Risk of colonization increases with length of stay • Other risk factors: • Poor hand hygiene of hospital personnel • Use of electronic rectal thermometers • Enteral tube feeding

  18. Why So Serious? • Both the incidence and severity of Clostridium difficileinfections have increased significantlyin the past decade • Clostridium difficileinfection rates in U.S. hospitals tripledbetween 2000 and 2005 • CDI rates in Canada have quadrupledsince 1997 • Increased rates directly attributed to an increase in mortality from 1.7% to 6.9%

  19. Why So Serious? • Causality attributed to emergence of specific strain-types of outbreaks known synonymously as: • North American pulsed-field type (NAP-1) • Toxinotype III • REA type BI • PCRribotype 027 • Emergence may be explained in part by patterns of antibiotic use in hospitals

  20. CDI Epidemic • North American pulsed-field type (NAP-1) • Highly resistant to fluoroquinolones • Carries deletion mutations in toxin regulatory gene • Results in higher levels of toxin production • 16 to 23 times more toxin A and B! • Results in significantly more serious disease • More resistant to standard therapy

  21. Fluoroquinolones • Most recent drug class implicated in hospital outbreaks of C. difficileinfections • Increasing fluoroquinolone resistance seen in: • Campylobacter, Salmonella, Clostridium difficile

  22. Treatment

  23. Treatment • Discontinue offending agent • Diarrhea may resolve in up to 25% of patients within 48 hours of discontinuation • Fluid and electrolyte replacement as necessary • Most patients will require antibiotics • Vancomycin • Metronidazole

  24. Treatment • Vancomycin(Oral) • IV does not achieve high enough gut concentrations • Contraindications, intolerance, or poor response to metronidazole • Retention enema delivery if ileus or inability to reach infection site • Concerns of vancomycin resistant enterococci (VRE) • Metronidazole • Drug of choice for mild to moderate CDI • Less expensive

  25. CDI Treatment Guidelines • Published by IDSA in 2010 • Metronidazole 500mg PO TID for 10-14 days • For mild to moderate CDI • Vancomycin125mg PO QID for 10-14 days • For initial episode of severe CDI • Vancomycin +/- 500mg metronidazole IV • For severe, complicated CDI • Vancomycin dose is 500mg PO QID + 500mg IV in 100mL NS rectally

  26. Treatment

  27. Contraindicated Regimens • Drugs that inhibit peristalsis or slow gut transit time should NOT be used in patients with fever or bloody stool • Diphenoxylate • Loperamide • Evidence to support an increase risk for development of hemolytic-uremic syndrome due to delayed intestinal clearance and increased toxin absorption

  28. Recurrence • Treatments similar in diarrhea resolution, incidence of side effects, and relapse rates • Relapse occurs in approximately 20% of patients • Relapse usually occurs within 1 to 2 weeks but can be delayed for up to 12 weeks • Frequency increases with subsequent recurrences • One prior episode: >40% recurrence risk • >2 prior episodes: >60% recurrence risk

  29. Recurrence • Risk factors for recurrence: • History of recurrence • Advancing age • Additional antimicrobials • Inadequate immune response to C. difficile toxins

  30. Recurrence & Treatment • Optimal management of multiple relapses is unclear • Alternative regimens: • Fecal transplantation • Vancomycin + rifampin • Vancomycin followed by rifaximin • Nitazoxanide • IVIG • Poor regimens • Bacitracin, cholestyramine, colestipol, fusidic acid, probiotics

  31. Recurrence • There is more than just C. difficileamidst normal gut flora • Further disruption of gut flora only causes susceptibility to other infections Where is the selective agent?

  32. Treatment Failure & Recurrence • Resistance to antimicrobials is rarely the cause of relapse • Relapse occurs because treatment: • Fails to eliminate C. difficilespores • Makes patients vulnerable to another infection by impairing normal flora

  33. CDI Treatment Guidelines • Fidaxomicin?

  34. Fidaxomicin (Dificid) • Narrow spectrum, macrocyclic antibiotic active against gram-positive aerobes and anarobes • Lacks activity against gram-negative bacteria • Poor activity against normal gut flora • Relatively selective activity against C. difficile • Inhibits bacterial protein synthesis by binding to sigma subunit of RNA polymerase • Negligible systemic absorption with oral administration • High fecal concentrations

  35. Fidaxomicin (Dificid) • As effective as vancomycin and may be associated with lower rates of relapse • 1st antimicrobial FDA approved by the FDA forCDI treatment in over 25 years • Orphan drug designation to all formulations for treatment of CDI in pediatric patients <16 years and younger • Administered 200mg PO BID

  36. Fidaxomicin versus Vancomycin for Clostridium difficileInfection Published in February 2011!

  37. Study Design • Prospective, multi-centered, double-blind, randomized, parallel-group trial • Non-inferiority study • All patients were enrolled at 52 sites in the United States and 15 sites in Canada • Conducted from May 2006 to August 2008

  38. Grading Recommendations

  39. Eligibility Criteria • > 16 years of age • Diagnosis of CDI • Presence of diarrhea defined as >3 unformed bowel movements in a 24-hour period • Presence of C. difficiletoxin A, B, or both in stool sample obtained within 48 hours of randomization • Could not be recipient of any potentially effective concurrent CDI treatments • Oral bacitracin, fusidic acid, rifaximin

  40. Exclusion Criteria • Patients receiving any potentially effective concurrent CDI treatments • Oral bacitracin, fusidic acid, rifaximin • Patients with: • Life-threatening or fulminant CDI • Toxic megacolon • Previous exposure to fidaxomicin • History of ulcerative colitis or Crohn’s disease • >1 occurrence of CDI within 3 months before study start

  41. Efficacy Outcomes • Primary endpoint • Rate of clinical cure in the modified intention-to-treat and per-protocol populations at the end of therapy or at the time of early withdrawal • Secondary endpoints • Recurrence of CDI during 28-day period after the end of the course of therapy • Global cure in the modified intention-to-treat and per-protocol populations

  42. Treatment • Randomized into two groups • Vancomycin125mg every 6 hours • Fidaxomicin200mg every 12 hours • Dosing scheduled with placebo for q6h dosing • Both medications were over-encapsulated to conceal identities • Oral dosing for 10 days

  43. Definitions • Modified intention-to-treat (MITT) population • Patients with documented CDI who underwent randomization and received at least one dose of study medication • Per-protocol population • Patients who received >1 dose of fidaxomicinwho received treatment for >3 days (treatment failure) or >8 days (clinical cure) • Documented adherence to protocol • Underwent end-of-therapy evaluation

  44. Study Enrollment • 629 patients enrolled and randomized • 596 included in modified intention-to-treat analysis (received > 1 dose of Dificid) • 548 included in per-protocol analysis

  45. Randomization

  46. Follow-up

  47. Follow-up • Assessed daily for clinical cure or clinical failure • Assessed weekly for 28 days after last dose for recurrence • Only patients who remained in the study and had a follow-up assessment between days 36 and 40 after randomization

More Related